U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07517653) titled 'Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma' on March 19.

Brief Summary: This study aims to investigate the efficacy and safety of SHR-1701 in combination with famitinib in the perioperative treatment of mucosal melanoma

Study Start Date: April 01

Study Type: INTERVENTIONAL

Condition: Melanoma

Intervention: DRUG: SHR-1701

Specifically targets mucosal melanoma, which accounts for 22.6% of melanoma cases in China

DRUG: Famitinib

Specifically targets mucosal melanoma, which accounts for 22.6% of melanoma cases in China

Recruitment Status: NOT_YET_RECRUITING

Sponsor...